Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenic obesity seems to impair insulin signaling in hepatocytes, resulting in increased de novo hepatic lipogenesis and inhibited hepatic β-oxidation [141].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, although the major source of hepatocellular triglycerides are adipose tissue-derived NEFA, the rate of hepatic de novo lipogenesis is also much greater in MASLD, further contributing to intrahepatic lipid accumulation [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Remarkably, the major fraction of hepatocellular triglycerides in people with obesity and MASLD is not derived from non-esterified fatty acids (NEFA) provided by dietary lipids, but from circulating NEFA released from adipose tissue [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
In the citing paper
“In individuals with MASLD and obesity, hepatic TG is reported to derive approximately 59% from circulating FFAs, 26% from DNL, and 15% from dietary sources [67].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [67]
In the citing paper
“IHTG was composed mainly of FFAs from SAT lipolysis (∼60%) and, to a lesser extent, FFAs from DNL (∼25%) or diet (∼15%).”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [23]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794 · cited 1×
“Given previous observations of higher fed-state DNL (23) and the known stimulatory effect of insulin on fatty acid synthesis (24), we were surprised that fed-state lipogenesis assessed at 1500 in tTRL TAG did not differ from values obtained in the fasting Figure 1 Model of lipid flux through the liver.”
ResultSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · cited 2×
“Insulin resistance has been shown to be associated with dysregulation of adiposederived fatty acid flux in the fasting state (10–12), and strong evidence exists demonstrating that in NAFLD patients, insulin does not suppress adipose tissue lipolysis to the same extent that it does in healthy individuals (13).”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360 · cited 6×
“Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. 2001.”
Influential
Research works printed but not linked: 6
- Donnelly, 2004, Diabetes., 56, A53
- 10.2337/diabetes.53.3.521 · DOI · Paper page
- Barrows, 2004, Diabetes., 56, A1388
- Timlin, 2004, Diabetes., 56, A338
- Baar, 2005, Am. J. Physiol., 288, E187
- Hellerstein, 1993, Am. J. Physiol., 265, E814
Cited by
Items 601–700 of 1,037
Fatty liver: Role of inflammation and fatty acid nutrition
Byrne, C. D. (2010) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2010.02.012 · Cited by 126
Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota
Doulberis, M., Kotronis, G., Gialamprinou, D., Kountouras, J., & Katsinelos, P. (2017) · Metabolism · doi:10.1016/j.metabol.2017.03.013 · Cited by 128
“In this respect, it has been estimated with an isotope technique that, in the presence of steatosis, approximately 60% of the hepatic triglycerides comes from the adipose tissue, 25% from de novo lipogenesis and 15% from dietary lipids [59].”
Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders
Pinkosky, S. L., Groot, P. H. E., Lalwani, N. D., & Steinberg, G. R. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.09.001 · Cited by 126
NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?
Stols-Gonçalves, D., Hovingh, G. K., Nieuwdorp, M., & Holleboom, A. G. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.08.008 · Cited by 118
Hormone-sensitive lipase: sixty years later
Recazens, E., Mouisel, É., & Langin, D. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101084 · Cited by 126
Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice
Arsov, T., Larter, C. Z., Nolan, C. J., Petrovsky, N., Goodnow, C. C., Teoh, N., Yeh, M. M., & Farrell, G. C. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.032 · Cited by 127
“If this were the case, the metabolic abnormalities in foz/foz mice, as well as the similar ones in another Alms1 mutant mouse [34], are likely to be secondary to obesity, insulin resistance, and hyperglycemia, as in mice subjected to intragastric over-nutrition [28], and in human NAFLD [4,22].”
BackgroundLipids and lipid management in diabetes
Jaiswal, M., Schinske, A., & Pop‐Busui, R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.12.001 · Cited by 129
“In addition, an increased de novo hepatic lipogenesis, VLDL and TG, was described in obesity and insulin resistance further contributing to lipoprotein abnormalities [25,26].”
BackgroundPrisingkorn, W., Prathomya, P., Jakovlić, I., Liu, H., Zhao, Y., & Wang, W. (2017) · BMC Genomics · doi:10.1186/s12864-017-4246-9 · Cited by 128
Cytochrome P450S and Alcoholic Liver Disease
Lu, Y., & Cederbaum, A. I. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180410091511 · Cited by 121
Podszun, M. C., Alawad, A. S., Lingala, S., Morris, N., Huang, W.-C. A., Yang, S., Schoenfeld, M., Rolt, A., Ouwerkerk, R., Valdez, K., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101710 · Cited by 114
“adipose tissue, followed by hepatic de novo lipogenesis (DNL) (26%) and dietary sources (14%) [18].”
BackgroundKawamura, S., Matsushita, Y., Kurosaki, S., Tange, M., Fujiwara, N., Hayata, Y., Hayakawa, Y., Suzuki, N., Hata, M., Tsuboi, M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci151895 · Cited by 115
“Although lipid influx to the liver from insulin-resistant adipose tissue and dietary fat is increased in patients with NASH, hepatic de novo lipogenesis is paradoxically enhanced (2, 3).”
BackgroundDeivanayagam, S., Mohammed, B. S., Vitola, B. E., Naguib, G. H., Keshen, T. H., Kirk, E. P., & Klein, S. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.2.257 · Cited by 116
“Increased release of fatty acids from subcutaneous adipose tissue into the systemic circulation can cause the following: 1) insulin resistance in liver and muscle, resulting in impaired insulin-mediated suppression of hepatic glucose production and insulin-mediated muscle glucose uptake (32); 2) dyslipidemia resulting…”
BackgroundGambino, R., Cassader, M., Pagano, G., Durazzo, M., & Musso, G. (2007) · Hepatology · doi:10.1002/hep.21631 · Cited by 117
Wu, J. H. Y., Lemaître, R. N., Imamura, F., King, I. B., Song, X., Spiegelman, D. L., Siscovick, D. S., & Mozaffarian, D. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.012054 · Cited by 128
Shojaee-Moradie, F., Cuthbertson, D. J., Barrett, M., Jackson, N. C., Herring, R., Thomas, E. L., Bell, J., Kemp, G. J., Wright, J., & Umpleby, A. M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2353 · Cited by 116
“lomicrons (3) which are generated when these lipoproteins”
BackgroundLiver Clock Protein BMAL1 Promotes de Novo Lipogenesis through Insulin-mTORC2-AKT Signaling
Zhang, D., Tong, X., Arthurs, B., Guha, A., Rui, L., Kamath, A., Inoki, K., & Yin, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.567628 · Cited by 115
“It has been proposed that constantly elevated de novo lipogenesis contributes to the pathogenesis of nonalcoholic fatty liver diseases (5, 7).”
BackgroundDoes nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
Santos, R. D., Valenti, L. V. C., & Romeo, S. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.029 · Cited by 123
Enooku, K., Nakagawa, H., Fujiwara, N., Kondo, M., Minami, T., Hoshida, Y., Shibahara, J., Tateishi, R., & Koike, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-47216-2 · Cited by 124
From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
Boccatonda, A., Andreetto, L., D’Ardes, D., Cocco, G., Rossi, I., Vicari, S., Schiavone, C., Cipollone, F., & Guagnano, M. T. (2023) · Biomedicines · doi:10.3390/biomedicines11030883 · Cited by 130
“Indeed, in NAFLD patients, DNL contributes to the synthesis of 26% of intrahepatic triglycerides, compared to 5% in healthy patients [47].”
BackgroundFang, D., Wan, Y., Shen, W., Cao, J., Sun, Z.-X., Yu, H., Zhang, Q., Cheng, W., Chen, J., & Ning, B. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1694-7 · Cited by 122
“NAFLD is one of the most frequent causes of abnormal liver function [1].”
BackgroundInfluentialStiede, K., Miao, W., Blanchette, H. S., Beysen, C., Harriman, G., Harwood, H. J., Kelley, H., Kapeller, R., Schmalbach, T., & Westlin, W. F. (2017) · Hepatology · doi:10.1002/hep.29246 · Cited by 114
“There exists both indirect and direct evidence that elevated lipogenesis provides a significant source of the fatty acids accumulating in the livers of patients with NAFLD.”
BackgroundJiang, M., Li, C., Liu, Q., Wang, A., & Lei, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00665 · Cited by 122
AMPK and the Endocrine Control of Metabolism
Townsend, L. K., & Steinberg, G. R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad012 · Cited by 119
Hepatic Glucokinase Expression Is Associated with Lipogenesis and Fatty Liver in Humans
Peter, A., Stefan, N., Cegan, A., Walenta, M., Wagner, S., Königsrainer, A., Königsrainer, I., Machicao, F., Schick, F., Häring, H.-U., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2017 · Cited by 115
“De novo lipogenesis has an important contribution to the pathophysiology of fatty liver because it provides almost one third of the accumulated hepatic triglycerides in patients with hepatosteatosis (5, 6).”
BackgroundFukuda, Y., Hashimoto, Y., Hamaguchi, M., Fukuda, T., Nakamura, N., Ohbora, A., Kato, T., Kojima, T., & Fukui, M. (2015) · Liver International · doi:10.1111/liv.12977 · Cited by 126
“There are three major sources of FFA in the liver: 60% from plasmatic non-esterified fatty acids, 25% from de novo lipogenesis and 15% from dietary fatty acids in the form of chylomicrons lipoproteins (27).”
BackgroundWei, J., Sun, X., Chen, Y., Li, Y., Song, L., Zhao, Z., Xu, B., Lin, Y., & Xu, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0356 · Cited by 118
Bessone, F., Dirchwolf, M., Rodil, M. A., Razori, M. V., & Roma, M. G. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14952 · Cited by 102
Macronutrients and the Adipose-Liver Axis in Obesity and Fatty Liver
Duwaerts, C. C., & Maher, J. J. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.02.001 · Cited by 125
Exercise Combats Hepatic Steatosis: Potential Mechanisms and Clinical Implications
Thyfault, J. P., & Rector, R. S. (2020) · Diabetes · doi:10.2337/dbi18-0043 · Cited by 109
“Tracer approaches in human patients with hepatic steatosis (measured in postabsorptive state) revealed that;60% of intrahepatic lipids were derived from circulating FFAs emerging from adipose depots via lipolysis (8).”
BackgroundInfluentialMeex, R. C. R., & Blaak, E. E. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900942 · Cited by 125
Endoplasmic Reticulum Stress and the Unfolded Protein Response
Kapoor, A., & Sanyal, A. J. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.004 · Cited by 119
Bitter, A., Rümmele, P., Klein, K., Kandel, B. A., Rieger, J. K., Nussler, A. K., Zanger, U. M., Trauner, M., Schwab, M. G., & Burk, O. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1348-x · Cited by 121
“2009), which may contribute to DNL being permanently up-regulated in NAFLD (Donnelly et al. 2005).”
BackgroundSuzuki, T., Shinjo, S., Arai, T., Kanai, M., & Goda, N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15087 · Cited by 119
Caputo, T., Gilardi, F., & Desvergne, B. (2017) · FEBS Letters · doi:10.1002/1873-3468.12742 · Cited by 123
Xian, Y., Weng, J., & Xu, F. L. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001263 · Cited by 130
“Tracer studies in individuals with obesity have demonstrated that ∼60% of liver TG content is derived from free fatty acids (FFAs) from adipose tissue.([68]) Obese individuals have increased visceral adipose tissue that could lead to IR and hyperinsulinemia, which will enhance adipose tissue lipolysis.”
BackgroundO’Farrell, M., Duke, G., Crowley, R., Buckley, D., Martins, E. B., Bhattacharya, D., Friedman, S. L., & Kemble, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-19459-z · Cited by 105
Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance
Savage, D. B., & Semple, R. K. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833b7782 · Cited by 121
Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver
Sánchez-Lozada, L. G., Mu, W., Roncal, C., Sautin, Y. Y., Abdelmalek, M., Reungjui, S., Le, M., Nakagawa, T., Lan, H. Y., Yu, X., et al. (2010) · European Journal of Nutrition · doi:10.1007/s00394-009-0042-x · Cited by 105
“Recent studies showed that 59% of TG within hepatocytes arose from the plasma-free fatty acid pool in the fed state [10].”
BackgroundResultNew diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
Ali, R., & Cusi, K. (2009) · Annals of Medicine · doi:10.1080/07853890802552437 · Cited by 110
“Adipose stores account for about 70% of the FFA used for hepatic fat synthesis in the setting of obesity and T2DM (40).”
BackgroundXi, Y., Wu, M., Li, H., Dong, S., Luo, E., Gu, M., Shen, X. Z., Jiang, Y., Liu, Y., & Liu, H. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000374037 · Cited by 114
de Meijer, V. E., Le, H. D., Meisel, J. A., Sharif, M. R. A., Pan, A., Nosé, V., & Puder, M. (2010) · Metabolism · doi:10.1016/j.metabol.2009.11.006 · Cited by 107
“Hepatic steatosis in patients with NAFLD is a consequence of increased free fatty acid delivery to the liver combined with increased de novo lipogenesis [25].”
BackgroundWu, D., Zheng, N.-R., Qi, K., Cheng, H., Sun, Z., Gao, B., Zhang, Y., Pang, W., Huangfu, C., Ji, S., et al. (2015) · Medical Gas Research · doi:10.1186/s13618-014-0022-y · Cited by 117
“Liver dysfunction could lead to dysregulation of lipid metabolism, including alterations in fatty acid biosynthesis, beta-oxidation and very low density lipoprotein (VLDL) secretion, which subsequently influences serum levels of cholesterol and lipoproteins [4,37,38].”
BackgroundSunny, N. E., Kalavalapalli, S., Bril, F., Garrett, T. J., Nautiyal, M., Mathew, J. T., Williams, C. M., & Cusi, K. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00161.2015 · Cited by 106
Rahman, M. M., Alam, M. N., Ulla, A., Sumi, F. A., Subhan, N., Khan, T., Sikder, B., Hossain, H., Reza, H. M., & Alam, M. A. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0539-x · Cited by 106
“With the progress of obesity, increased hepatic lipogenesis and serum fatty acid lead to excess accumulation of liver lipid which result in fatty liver, impaired liver function, and eventually liver failure [6].”
Mu, H., Shen, H., Liu, J., Xie, F., Zhang, W., & Mai, K. (2018) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2018.04.017 · Cited by 113
Complex roles of nicotinamide N-methyltransferase in cancer progression
Wang, W., Yang, C., Wang, T., & Deng, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04713-z · Cited by 115
“LIHC is characterized by a series of metabolic alterations such as increased glucose uptake and lactate production [91, 92], upregulated de novo lipogenesis and NADPH production [93, 94], accelerated glutamine consumption [95], elevated amino acids metabolism, and GSH synthesis [96–99], as well as attenuated TCA cycle…”
BackgroundSantamarina, A. B., de Oliveira, J. L., da Silva, F. P., Carnier, J., Mennitti, L. V., de Santana, A. A., Gabriel, H. I. D. S., Ribeiro, E. B., do Nascimento, C. M. O., Lira, F. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141227 · Cited by 114
“The high hepatic influx of NEFA increases the secretion of very low density lipoproteins (VLDLs) and apolipoprotein B in the circulation, contributing to an increased hepatic glucose production by gluconeogenesis [6] and the activation of the de novo lipogenesis pathway [7].”
BackgroundThe genetics of familial combined hyperlipidaemia
Brouwers, M. C. G. J., van Greevenbroek, M. M. J., Stehouwer, C. D. A., de Graaf, J., & Stalenhoef, A. F. H. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.15 · Cited by 109
Non-alcoholic fatty liver disease and cardiovascular risk
Brea, Á., & Puzo, J. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.085 · Cited by 122
“After a diet high in sugars, in the IR state associated with NAFLD, the uptake of glucose by the muscles ends up being diverted towards the liver where it then contributes to DNL [16].”
BackgroundNonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R., & Belfiore, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122933 · Cited by 107
The pathophysiology of MASLD: an immunometabolic perspective
Schwärzler, J., Grabherr, F., Grander, C., Adolph, T. E., & Tilg, H. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2294046 · Cited by 117
“…alterations regarding lipid metabolism are involved in the pathogenesis of MASLD: an increased supply of FFAs, either derived from the diet or VAT depots, to the liver-induced DNL [49,50], while an impairment of fatty acid oxidation and export of lipids from the liver was observed [51,52].”
Lipid-associated macrophages between aggravation and alleviation of metabolic diseases
Xu, R., Vujić, N., Bianco, V., Reinisch, I., Kratky, D., Krstic, J., & Prokesch, A. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.04.009 · Cited by 95
“The dysregulation between lipogenesis and lipid catabolism by mitochondrial fatty acid oxidation (FAO) in hepatocytes can lead to fatty acid accumulation in the liver, promoting steatosis and MASH [60].”
BackgroundLipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
Iturbe-Rey, S., Maccali, C., Arrese, M. A., Aspichueta, P., de Oliveira, C. P. M. S., Castro, R. E., Lapitz, A., Izquierdo‐Sánchez, L., Bujanda, L., Perugorria, M. J., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119053 · Cited by 131
Genomic aspects of NAFLD pathogenesis
Naik, A., Košir, R., & Rozman, D. (2013) · Genomics · doi:10.1016/j.ygeno.2013.03.007 · Cited by 112
“, Genomic aspects of NAFLD pathoge E D P R O O F Isotopic studies in liver biopsies from obese, hypertriglyceridemic and hyperinsulinemic NAFLD patients have revealed elevated levels of adipose-derived free fatty acid flux and de novo lipogenesis [15], along with compromised fatty acid oxidation and secretion [16].”
BackgroundFatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity
Walle, P., Takkunen, M. J., Männistö, V., Vaittinen, M., Lankinen, M. A., Kärjä, V. J., Käkelä, P., Ågren, J., Tiainen, M., Schwab, U., et al. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.011 · Cited by 115
“Accordingly, increased activity of DNL has previously been reported in NAFLD [49-52] and it has been suggested to have a role in hepatic fat accumulation [52, 53].”
BackgroundKitae, A., Hashimoto, Y., Hamaguchi, M., Obora, A., Kojima, T., & Fukui, M. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/5121574 · Cited by 115
Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges
Kuchay, M. S., Martínez‐Montoro, J. I., Choudhary, N. S., Fernández‐García, J. C., & Ramos‐Molina, B. (2021) · Biomedicines · doi:10.3390/biomedicines9101346 · Cited by 118
“In this line, the three major sources of hepatic fatty acids are (1) adipose tissue lipolysis, which is the source of around 60% of FFAs present in the circulation (and even higher under insulin resistance conditions) [2]; (2) excessive carbohydrates levels (especially glucose and fructose), which are converted into F…”
BackgroundNassir, F., Okunade, A. L., Brunt, E. M., & Abumrad, N. A. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m037812 · Cited by 117
Ruiz‐Ramírez, A., Salgado, M. C., Peñeda-Flores, J. A., Zapata, E., Massó, F., & El‐Hafidi, M. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00631.2010 · Cited by 113
“In the liver, FFAs can be incorporated into triglycerides that accumulate and lead to nonalcoholic fatty liver disease, the primary hepatic complication of obesity (13, 57).”
BackgroundHodson, L., Bickerton, A. S. T., McQuaid, S. E., Roberts, R., Karpe, F., Frayn, K. N., & Fielding, B. A. (2007) · Diabetes · doi:10.2337/db07-0654 · Cited by 102
“In the postprandial state, the contribution of DNL fatty acids has been reported to be between 8 and 13% to Sf 60–400 TGs in healthy individuals (13,15,17,35), and up to 26% of DNL fatty acids to TRLs has been reported for individuals with nonalcoholic fatty liver disease (15) and hypertriglyceridemia (17).”
BackgroundResultHu, Y., He, W., Huang, Y., Xiang, H., Guo, J., Che, Y., Cheng, X., Hu, F., Hu, M., Ma, T., et al. (2021) · Hepatology · doi:10.1002/hep.32045 · Cited by 128
Duivenvoorden, I., Voshol, P. J., Rensen, P. C. N., van Duyvenvoorde, W., Romijn, J. A., EMEIS, J. J., Havekes, L. M., & Nieuwenhuizen, W. F. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.1.312 · Cited by 106
Luukkonen, P. K., Tukiainen, T., Juuti, A., Sammalkorpi, H., Haridas, P. A. N., Niemelä, O., Arola, J., Orho-Melander, M., Hakkarainen, A., Kovanen, P. T., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132158 · Cited by 99
“This could be secondary to hyperinsulinemia and increased de novo lipogenesis (DNL) in NAFLD associated with insulin resistance (9) or a consequence of HSD17B13, because overexpression of this protein caused steatosis in mice and increased lipid droplet size and number in cultured human hepatocytes (6).”
BackgroundInfluentialPathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Kuchay, M. S., Choudhary, N. S., & Ramos‐Molina, B. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00951.2024 · Cited by 117
A Dual Sugar Challenge Test for Lipogenic Sensitivity to Dietary Fructose
Hudgins, L. C., Parker, T. S., Levine, D. M., & Hellerstein, M. K. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2007 · Cited by 105
Kusunoki, J., Kanatani, A., & Moller, D. E. (2006) · Endocrine · doi:10.1385/endo:29:1:91 · Cited by 119
Mouse models of inherited lipodystrophy
Savage, D. B. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.002907 · Cited by 105
Obara, N., Fukushima, K., Ueno, Y., Wakui, Y., Kimura, O. S., Tamai, K., Kakazu, E., Inoue, J., Kondo, Y., Ogawa, N., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.029 · Cited by 111
“One of the noted biochemical changes seen in the HF-T group was the elevation of plasma FFA, almost all of which is derived from adipose tissue and accumulates in the liver as TG in a dose-dependent fashion [7].”
BackgroundWree, A., Schlattjan, M., Bechmann, L. P., Claudel, T., Sowa, J., Stojaković, T., Scharnagl, H., Köfeler, H. C., Baba, H. A., Gerken, G., et al. (2014) · Metabolism · doi:10.1016/j.metabol.2014.09.001 · Cited by 108
“62% of FFAs originate from the vWAT [9].”
BackgroundZhu, W., Chen, S., Li, Z., Zhao, X., Li, W., Sun, Y., Zhang, Z., Ling, W., & Feng, X. (2014) · Nutrition & Metabolism · doi:10.1186/1743-7075-11-35 · Cited by 104
“Previous studies have confirmed that hepatic steatosis mostly results from the increased free fatty acid (FFA) supply due to increased lipolysis and/or increased intake of dietary fat, which contributes to 60% of hepatic fat content [3].”
BackgroundLiver NF‐κB and AP‐1 DNA Binding in Obese Patients
Videla, L. A., Tapia, G., Rodrigo, R., Pettinelli, P., Haim, D., Santibáñez, C., Araya, A. V., Smok, G., Csendes, A., Gutiérrez, L., et al. (2009) · Obesity · doi:10.1038/oby.2008.601 · Cited by 116
“In addition, enhanced peripheral FA mobilization may also contribute to TAG accumulation by re- directing FAs to TAG synthesis due to IR (4,5).”
BackgroundStefan, N., Peter, A., Čegan, A., Staiger, H., Machann, J., Schick, F., Claussen, C. D., Fritsche, A., Häring, H., & Schleicher, E. (2008) · Diabetologia · doi:10.1007/s00125-008-0938-7 · Cited by 111
“However, fatty acids also derive from de novo lipogenesis in the liver [12, 15, 16], which is predominantly regulated by sterolregulatory binding protein 1c [17].”
BackgroundInfluentialThe genetic architecture of NAFLD among inbred strains of mice
Hui, S. T., Parks, B. W., Org, E., Norheim, F., Che, N., Pan, C., Castellani, L. W., Charugundla, S., Dirks, D. L., Psychogios, N., et al. (2015) · eLife · doi:10.7554/elife.05607 · Cited by 104
“DOI: 10.7554/eLife.05607 5 of 28 Hepatic TG accumulation is highly correlated with plasma cholesterol, insulin resistance, and adiposity A substantial amount of hepatic TG is derived from FAs of extrahepatic sources, in particular, the white adipose tissue.”
BackgroundInfluentialMesenteric Fat Lipolysis Mediates Obesity-Associated Hepatic Steatosis and Insulin Resistance
Wueest, S., Item, F., Lucchini, F. C., Challa, T. D., Müller, W., Blüher, M., & Konrad, D. (2016) · Diabetes · doi:10.2337/db15-0941 · Cited by 96
“Accordingly, in humans, up to 59% of FFA bound in liver TGs may arise from plasma FFA (40).”
BackgroundNon-alcoholic fatty liver disease and associated dietary and lifestyle risk factors
Al-Dayyat, H. M., Rayyan, Y. M., & Tayyem, R. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.016 · Cited by 115
FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to Specific DNA Motifs
Pittol, J. M. R., Milona, A., Morris, I., Willemsen, E. C. L., van der Veen, S. W., Kalkhoven, E., & van Mil, S. W. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.07.036 · Cited by 105
Growth Hormone Inhibits Hepatic De Novo Lipogenesis in Adult Mice
Cordoba-Chacon, J., Majumdar, N., List, E. O., Diaz-Ruiz, A., Frank, S. J., Manzano, A., Bartrons, R., Puchowicz, M., Kopchick, J. J., & Kineman, R. D. (2015) · Diabetes · doi:10.2337/db15-0370 · Cited by 102
“of new fatty acids from glucose (6)) also plays a significant role in NAFLD progression (5; 7-9), 48 which may in part be driven by hyperinsulinemia (1).”
BackgroundQueipo‐Ortuño, M. I., Escoté, X., Ceperuelo‐Mallafré, V., Garrido‐Sánchez, L., Miranda, M., Clemente‐Postigo, M., Pérez‐Pérez, R., Peral, B., Cardona, F., Fernández‐Real, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048605 · Cited by 102
Brindley, D. N., Kok, B. P., Kienesberger, P. C., Lehner, R. S., & Dyck, J. R. B. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00509.2009 · Cited by 108
PNPLA3, TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease
Simons, N., Isaacs, A. J., Koek, G. H., Kuč, S., Schaper, N. C., & Brouwers, M. C. G. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.020 · Cited by 102
Chen, J., Chen, J., Huang, J., Li, Z., Gong, Y., Zou, B., Liu, X., Ding, L., Li, P., Zhu, Z., et al. (2019) · Aging · doi:10.18632/aging.102488 · Cited by 117
“Elevated liver lipogenesis is an important contributing factor in the development and progression of NAFLD [27].”
BackgroundBabu, A. F., Csader, S., Lok, J., Gómez-Gallego, C., Hanhineva, K., El-Nezami, H., & Schwab, U. (2021) · Nutrients · doi:10.3390/nu13093135 · Cited by 88
“In the liver, these FFAs can either be synthesized to triglycerides and stored as lipid droplets in the liver leading to steatosis [57], excreted in very low-density lipoproteins (VLDL) [58], or oxidized in hepatic mitochondria (β-oxidation) [59].”
BackgroundThe role of ChREBP in carbohydrate sensing and NAFLD development
Régnier, M., Carbinatti, T., Parlati, L., Benhamed, F., & Postic, C. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00809-4 · Cited by 101
Cimini, F. A., Barchetta, I., Carotti, S., Bertoccini, L., Baroni, M. G., Vespasiani-Gentilucci, U., Cavallo, M.-G., & Morini, S. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i19.3407 · Cited by 101
Smati, S., Polizzi, A., Fougerat, A., Ellero‐Simatos, S., Blum, Y., Lippi, Y., Régnier, M., Laroyenne, A., Huillet, M., Arif, M., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323323 · Cited by 104
Oxidative Stress in Non-Alcoholic Fatty Liver Disease
Smirne, C., Croce, E., Benedetto, D. D., Cantaluppi, V., Comi, C., Sainaghi, P. P., Minisini, R., Grossini, E., & Pirisi, M. (2022) · Livers · doi:10.3390/livers2010003 · Cited by 111
“The liver, having remained largely insulin sensitive and being exposed to increasing levels of blood glucose, serum triglycerides, and insulin, enters a hyperanabolic state, continuing to synthesize and store lipids [15].”
BackgroundPal, S. C., & Méndez‐Sánchez, N. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i25.3999 · Cited by 108
Lack of liver glycogen causes hepatic insulin resistance and steatosis in mice
Irimia, J. M., Meyer, C. M., Segvich, D. M., Surendran, S., DePaoli-Roach, A. A., Morral, N., & Roach, P. J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.786525 · Cited by 101
“Compromised glucose disposal as glycogen may further contribute to hepatic steatosis by diverting excess carbohydrates into fatty acids by the de novo lipogenesis pathway (DNL) (16, 17).”
BackgroundInfluentialApolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Yao, Z., & Wang, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc70 · Cited by 100
“fatty acids of adipocyte origin or released from hydrolysis of remnant lipoproteins), as well as endogenous de-novo lipogenesis (DNL), are the major substrate for hepatic triglyceride synthesis [13].”
BackgroundJohnson, S. M., Bao, H., McMahon, C. E., Chen, Y., Burr, S. D., Anderson, A. M., Madeyski-Bengtson, K., Lindén, D., Han, X., & Liu, J. (2024) · Nature Communications · doi:10.1038/s41467-024-49224-x · Cited by 100
“In addition, activation of another transcription factor liver X receptor (LXR) by cellular oxysterols or pharmacological agonists can also activate SREBP-1c, facilitating DNL and hepatic TG secretion 30,31 .”
Metabolic Health, Insulin, and Breast Cancer: Why Oncologists Should Care About Insulin
Yee, L. D., Mortimer, J. E., Natarajan, R. D., Dietze, E. C., & Seewaldt, V. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00058 · Cited by 113
Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders
Hazlehurst, J. M., & Tomlinson, J. W. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0296 · Cited by 97
Endoplasmic Reticulum Stress and the Unfolded Protein Response in Nonalcoholic Fatty Liver Disease
Gentile, C. L., Frye, M. A., & Pagliassotti, M. J. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3790 · Cited by 108
“A large portion of the elevated hepatic triglyceride stores in NAFLD appear to arise from re-esterification of circulating free fatty acids (32).”
BackgroundLipid storage by adipose tissue macrophages regulates systemic glucose tolerance
Aouadi, M., Vangala, P., Yawe, J. C., Tencerova, M., Nicoloro, S. M., Cohen, J. L., Shen, Y., & Czech, M. P. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00187.2014 · Cited by 88
Hepatic De Novo Lipogenesis in Obese Youth Is Modulated by a Common Variant in the GCKR Gene
Santoro, N., Caprio, S., Pierpont, B., Van Name, M., Savoye, M., & Parks, E. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1587 · Cited by 94
“Moreover, given the strong relationship between hepatic fat content and DNL (1, 12), to test the sole effect of the gene variant and rule out the effect of fatty liver on DNL, the two groups were matched also for hepatic fat content.”
BackgroundMethodSelf-citationGut Microbiota and Lifestyle Interventions in NAFLD
Houghton, D., Stewart, C. J., Day, C. P., & Trenell, M. I. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040447 · Cited by 114
“patients [70,71], thus regulation of fat intake has been highlighted as potential target for therapeutic intervention to reduce hepatic lipids [72].”
BackgroundIntestinal, but not hepatic, ChREBP is required for fructose tolerance
Kim, M., Astapova, I. I., Flier, S. N., Hannou, S. A., Doridot, L., Sargsyan, A., Kou, H. H., Fowler, A. J., Liang, G., & Herman, M. A. (2017) · JCI Insight · doi:10.1172/jci.insight.96703 · Cited by 93
Carpentier, A. C. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00620.2020 · Cited by 108
Role of adipose tissue in methionine–choline-deficient model of non-alcoholic steatohepatitis (NASH)
Jha, P., Knopf, A., Köfeler, H. C., Mueller, M., Lackner, C., Höefler, G., Claudel, T., & Trauner, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.02.012 · Cited by 105
“Obesity, insulin resistance, and NAFLD are all associated with increased adipose tissue lipolysis [12,13].”
BackgroundInfluentialEffect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease
Collison, K. S., Maqbool, Z. M., Saleh, S. M., Inglis, A. L., Makhoul, N. J., Bakheet, R., Al‐Johi, M. A., Al‐Rabiah, R. K., Zaidi, M. Z., & Al-Mohanna, F. A. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800418-jlr200 · Cited by 104
Metadata
- Authors
- Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Parks, Elizabeth J.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-05-02
- Volume
- 115
- Issue
- 5
- Pages
- 1343-1351
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1087172
- OpenAlex
- W1985592156
- Semantic Scholar
- ed7633369ab77ee37699d391fe0fa59627da0df8
- Cited by
- 3,604
- References
- 50
- Citations by year
- 2026: 158 · 2025: 199 · 2024: 230 · 2023: 268 · 2022: 254 · 2021: 264 · 2020: 229 · 2019: 221 · 2018: 222 · 2017: 184 · 2016: 200 · 2015: 185 · 2014: 163 · 2013: 147 · 2012: 127
- FWCI
- 44.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Minnesota
- National Institutes of Health (RR00400)
- National Institute of Diabetes and Digestive and Kidney Diseases (R03DK058286)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (PAR-98-086)
- National Center for Research Resources (M01RR000400)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- non-alcoholic fatty liver disease, hepatic triglycerides, de novo lipogenesis, free fatty acids, VLDL, stable isotope tracers, fatty acid sources, hepatic lipid accumulation, obesity, hypertriglyceridemia, hyperinsulinemia
- MeSH terms
- Adult, Fatty Acids, Fatty Liver, Female, Humans, Lipoproteins, Liver, Male, Middle Aged, Time Factors, Triglycerides, Cholesterol, VLDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.